Journal of The American Academy of Dermatology (JAAD)

Use of systemic immunomodulating medications in pregnant women with atopic dermatitis: a nationwide US study

Funding sources: Dr. Hartman is funded by the Department of Defense and the VA Integrated Service Network 1 (VISN-1). Conflicts of Interest: Mr. Kim is a paid consultant at Verve Therapeutics and SeQure Dx, unrelated to this research. Dr. Hartman is a scientific officer for Evereden, unrelated to this research. Mr. Kim and Dr. Hartman’s interests were reviewed and are managed by Mass General Brigham in accordance with their conflict-of-interest policies.

Topical sirolimus effectively treats the angiofibromas of tuberous sclerosis; however, can it improve neurofibromas (NFs)? Neurofibromatosis type 1 (NF1) is characterized by café au lait macules, skin-fold freckling (Crowe sign), Lisch nodules (melanocytic iris hamartomas), optic gliomas, and bone deformities. Cutaneous NFs, although benign, have significant psychosocial implications due to pruritus, physical disfigurement, and sometimes pain.

This paper is only available as a PDF. To read, Please Download here. Funding Sources: John S. Barbieri is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number 1K23AR078930 © 2023 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.

Prurigo nodularis (PN) is an extremely pruritic, chronic inflammatory skin disease. Little is known about systemic inflammation in PN. To characterize plasma inflammatory biomarkers in PN patients and investigate the presence of disease endotypes. In this cross-sectional study, Olink proteomic analysis was performed on plasma samples from PN patients (n=29) and healthy controls (n=18).

Retrospective analysis of risks and benefits of trimethoprim/sulfamethoxazole as prophylaxis for Pneumocystis Jiroveci Pneumonia in patients with dermatologic disease

Interpreting with Caution the Lack of Association between Isotretinoin, Depression and Suicide

Article info Publication history Accepted: January 27, 2023 Received in revised form: January 9, 2023 Received: October 19, 2022 Publication stage In Press Journal Pre-Proof Footnotes Disclosures: Dr. Uno reports prior consulting/advisory payments from Roche. Dr. Syngal reports prior consulting fees from Myriad Genetic Laboratories, Inc., and inventor/royalties from the PREMM® model.

Concerns remain regarding whether oral antibiotic or isotretinoin use for acne is associated with increased risk of inflammatory bowel disease (IBD); little is known about whether acne itself is associated with IBD. To determine whether isotretinoin exposure, oral tetracycline-class antibiotic exposure, and/or acne itself are associated with IBD.

Article info Publication history Published online: January 04, 2023 Accepted: October 24, 2022 Footnotes Funding sources: The collection of cancer incidence data used in this registry study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section 103885; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 5NU58DP003862-04/DP003862; the National Cancer Institute’s...